^Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, et al. (April 1999). "Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements". Journal of Medicinal Chemistry. 42 (7): 1213–24.
doi:
10.1021/jm9805384.
PMID10197965.
^Santos MM, Moreira R (October 2007). "Michael acceptors as cysteine protease inhibitors". Mini Reviews in Medicinal Chemistry. 7 (10): 1040–50.
doi:
10.2174/138955707782110105.
PMID17979807.
^Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, et al. (April 1999). "Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements". Journal of Medicinal Chemistry. 42 (7): 1213–24.
doi:
10.1021/jm9805384.
PMID10197965.
^Santos MM, Moreira R (October 2007). "Michael acceptors as cysteine protease inhibitors". Mini Reviews in Medicinal Chemistry. 7 (10): 1040–50.
doi:
10.2174/138955707782110105.
PMID17979807.